Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.
Roca E, Berruti A, Sbiera S, Rapa I, Oneda E, Sperone P, Ronchi CL, Ferrari L, Grisanti S, Germano A, Zaggia B, Scagliotti GV, Fassnacht M, Volante M, Terzolo M, Papotti M. Roca E, et al. Among authors: zaggia b. Endocr Relat Cancer. 2017 Jul;24(7):319-327. doi: 10.1530/ERC-17-0095. Epub 2017 Apr 21. Endocr Relat Cancer. 2017. PMID: 28432084 Free article.
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A. Sperone P, et al. Among authors: zaggia b. Endocr Relat Cancer. 2010 Apr 21;17(2):445-53. doi: 10.1677/ERC-09-0281. Print 2010 Jun. Endocr Relat Cancer. 2010. PMID: 20410174 Clinical Trial.
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P, Mannelli M, Boscaro M, Arvat E, Tiberio G, Hahner S, Zaggia B, Porpiglia F, Volante M, Fassnacht M, Terzolo M. Berruti A, et al. Among authors: zaggia b. J Clin Endocrinol Metab. 2017 Apr 1;102(4):1358-1365. doi: 10.1210/jc.2016-2894. J Clin Endocrinol Metab. 2017. PMID: 28324035 Free article.
Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S, Ardito A, Daffara F, Zaggia B, Germano A, Berruti A, Di Carlo F. De Francia S, et al. Among authors: zaggia b. Minerva Endocrinol. 2012 Mar;37(1):9-23. Minerva Endocrinol. 2012. PMID: 22382612 Review.
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, Perotti P, Feelders RA, deVries JH, Zaggia B, De Francia S, Volante M, Haak HR, Allolio B, Al Ghuzlan A, Fassnacht M, Berruti A. Terzolo M, et al. Among authors: zaggia b. Eur J Endocrinol. 2013 Jul 29;169(3):263-70. doi: 10.1530/EJE-13-0242. Print 2013 Sep. Eur J Endocrinol. 2013. PMID: 23704714 Free article.
Practical treatment using mitotane for adrenocortical carcinoma.
Terzolo M, Zaggia B, Allasino B, De Francia S. Terzolo M, et al. Among authors: zaggia b. Curr Opin Endocrinol Diabetes Obes. 2014 Jun;21(3):159-65. doi: 10.1097/MED.0000000000000056. Curr Opin Endocrinol Diabetes Obes. 2014. PMID: 24732405 Free article. Review.
21 results